Cost pressure of the new hepatitis C drugs in Canada = Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada.: H82-25/2016-PDF
"The pricing, utilization and cost related to the direct-acting antivirals (DAAs) for the treatment of hepatitis C has become a critical issue for public plans, private insurers and patients. This study provides insight into the use, pricing and cost of DAAs in Canada and internationally in 2015, along with a retrospective look at the recent trends. The international analysis focuses on the PMPRB7 countries: France, Germany, Italy, Sweden, Switzerland, the United Kingdom (UK) and the United States (US). Results for the Canadian market are reported at the national level, as well as for the private and public market segments."
Permanent link to this Catalogue record:
|Department/Agency|| Canada. Patented Medicine Prices Review Board. |
National Prescription Drug Utilization Information System (Canada)
|Title||Cost pressure of the new hepatitis C drugs in Canada = Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada.|
|Variant title||Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada|
|Language||Bilingual-[English | French]|
|Electronic document|| |
Archived information is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact the authoring department to request a format other than those available.
Note: The URLs contained in this/these document(s) may no longer be functionalHaving trouble opening this document?
|Note(s)|| Caption title. |
At head of title: National Prescription Drug Utilization Information System.
Text in English and French.
|Publishing information||[Ottawa] : Patented Medicine Prices Review Board, |
|Description|| p. : col. charts|
|Catalogue number|| |
|Subject terms||Hepatitis, Drugs, Prices|
- Date modified: